FOXO4-DRI vs Semax
Side-by-side comparison of key properties, dosing, and research.
- Summary
- FOXO4-DRI is a D-retro-inverso peptide derived from the FOXO4 protein that selectively induces apoptosis in senescent cells. By disrupting the FOXO4-p53 interaction that keeps senescent cells alive, it triggers programmed cell death specifically in these aging, pro-inflammatory cells while sparing healthy tissue.
- Semax is a synthetic heptapeptide derived from ACTH developed in Russia. It is a potent nootropic that enhances memory, focus, and provides neuroprotection. Approved in Russia for cognitive disorders, stroke recovery, and traumatic brain injury.
- Half-Life
- Estimated 2-4 hours (D-amino acid confers resistance to proteolysis)
- Minutes (but effects persist for hours via BDNF induction)
- Admin Route
- Subcutaneous, Intraperitoneal (research)
- Intranasal, SubQ
- Research
- —
- —
- Typical Dose
- 5 mg/kg in rodent studies; human equivalent approximately 0.5-1 mg/kg
- 0.25–1 mg (250–1000 mcg)
- Frequency
- 3 consecutive days per cycle
- 1–2 times daily
- Key Benefits
- Selectively clears senescent cells (senolytics)
- Reduces senescence-associated secretory phenotype (SASP) and chronic inflammation
- Demonstrated restoration of physical fitness in aged mice
- May improve healthspan and reduce age-related tissue dysfunction
- Potential for treatment of age-related pathologies driven by cellular senescence
- Does not affect healthy non-senescent cells at therapeutic doses
- Enhances memory and learning
- Improves focus and concentration
- Increases mental energy and motivation
- Provides neuroprotection via BDNF and NGF upregulation
- Reduces cognitive decline
- May alleviate ADHD symptoms
- Supports recovery from brain injury and stroke
- Fast-acting — effects within 30–60 minutes
- Approved in Russia for cognitive disorders and stroke recovery
- Side Effects
- Limited human data; largely preclinical evidence
- Possible temporary inflammatory response as senescent cells are cleared (senolytic effect)
- Weight loss observed at high doses in rodent studies
- Unknown long-term safety profile in humans
- Headache (rare, often from higher doses)
- Anxiety or overstimulation at high doses
- Sleep disruption if dosed too late
- Irritability (uncommon)
- Stacks With
- —
- —